InMed Pharmaceuticals
5 hedge funds and large institutions have $13.3K invested in InMed Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
6.26% less ownership
Funds ownership: 6.79% → 0.53% (-6.3%)
94% less capital invested
Capital invested by funds: $227K → $13.3K (-$213K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SS
SBI Securities
Tokyo,
Japan
|
+$1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$177K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$14.4K |
| 3 |
DB
Danske Bank
Copenhagen K,
Denmark
|
-$5 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $12.6K | -$14.4K | -4,302 | -41% |
|
|
SS
2
SBI Securities
Tokyo,
Japan
| $621 | +$1K | +300 | New |
|
|
AWM
3
AllSquare Wealth Management
Albany,
New York
| $2 | – | – | – |
|
|
FDCDDQ
4
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $2 | – | – | – |
|
|
AI
5
AdvisorShares Investments
Bethesda,
Maryland
| – | -$177K | -38,460 | Closed |
|
|
DB
6
Danske Bank
Copenhagen K,
Denmark
| – | -$5 | -1 | Closed |
|
|
BCV
7
Banque Cantonale Vaudoise
Lausanne,
Switzerland
| – | +$20 | +6 | New |
|
INM Hedge Fund Activity: Q1 2025 in Review
5 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q1 2025, worth a combined $13.3K — down 94% from $227K a quarter earlier.
Fund positioning in INM was balanced in Q1 2025: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was SBI Securities, opening a new position worth an estimated $1K. The largest seller was AdvisorShares Investments, exiting entirely with an estimated $177K sold.
- 5 institutional investors held InMed Pharmaceuticals (INM) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $13.3K of InMed Pharmaceuticals stock for Q1 2025, down 94% quarter-over-quarter.
- 2 funds opened new InMed Pharmaceuticals positions in Q1 2025 and 2 closed out, a net change of 0 holders.
- The largest InMed Pharmaceuticals buyer in Q1 2025 was SBI Securities, an estimated $1K added.
- The largest InMed Pharmaceuticals seller in Q1 2025 was AdvisorShares Investments, an estimated $177K sold.
Based on aggregated 13F filings for Q1 2025.